Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2881–2904 of 10,535 matching trials from the live ClinicalTrials.gov search.

Filters: Active, not recruiting Clear all

Conditions: Healthy
Interventions: Ketamine Hydrochloride; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 55 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Primary Immune Thrombocytopenia
Interventions: efgartigimod PH20 SC; Biological
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 5
States / cities: Bentonville, Arkansas • Washington D.C., District of Columbia • Fort Wayne, Indiana + 2 more

Conditions: Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Sarcoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions: Computed Tomography with Contrast, Microwave Ablation, Questionnaire Administration, Wedge Excision; Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Melanoma
Interventions: Ensartinib, ALKATI by Customized Nanostring Assay; Drug · Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 4
States / cities: Middletown, New Jersey • Montvale, New Jersey • East White Plains, New York + 1 more

Conditions: Brain Cancer
Interventions: Optune (NovoTTF-100A); Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 9
States / cities: Los Angeles, California • Denver, Colorado • Miami, Florida + 5 more

Conditions: Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
Interventions: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration; Drug · Biological · Radiation + 1 more
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2028
U.S. locations: 30
States / cities: Jacksonville, Florida • Warrenville, Illinois • Baltimore, Maryland + 23 more

Conditions: Breast Cancer
Interventions: Afuresertib, Afuresertib/placebo; Drug
Lead sponsor: Laekna Limited; Industry
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Santa Monica, California • Atlanta, Georgia • Iowa City, Iowa + 3 more

Conditions: Eosinophilic Esophagitis
Interventions: General education control, Decision support tool; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Sickle Cell Disease
Interventions: Briquilimab, Filgrastim, Abatacept, Sirolimus, Cyclophosphamide; Biological · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 4 Years to 100 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck Cancer
Interventions: Atezolizumab, Tocilizumab, Tiragolumab; Biological
Lead sponsor: Alain Algazi; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer
Interventions: Letrozole, Ribociclib, Placebo; Drug
Lead sponsor: Qamar Khan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 13
States / cities: Little Rock, Arkansas • Duarte, California • Santa Ana, California + 9 more

Conditions: Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, Recurrent CNS Tumor, Adult, Recurrent, CNS Tumor, Childhood, Refractory Primary Malignant Central Nervous System Neoplasm
Interventions: SC-CAR4BRAIN; Biological
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 1 Year to 26 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2043
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia 3, Spinocerebellar Ataxia Type 6, MSA-C
Interventions: BHV-4157; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis, Post Traumatic Deformity, Complications; Arthroplasty, Deformity of Limb
Interventions: Vanguard SSK 360 with PS Bearing, Vanguard SSK 360 with PSC bearing, Vanguard DA 360, Vanguard 360 TiNbN Femur with PS bearing, Vanguard 360 TiNbN Femur with PSC bearing; Device
Lead sponsor: Zimmer Biomet; Industry
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2031
U.S. locations: 4
States / cities: Morton Grove, Illinois • Henderson, Nevada • Salt Lake City, Utah + 1 more

Conditions: Kidney Disease, Renal Insufficiency Chronic, Kidney Failure, Chronic, Renal Impairment, Renal Insufficiency, End Stage Kidney Disease
Interventions: LY3841136; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Miami Lakes, Florida • Orlando, Florida

Conditions: Uveal Melanoma
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 4
States / cities: Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania + 1 more

Conditions: Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma, Refractory Glioblastoma, Refractory Malignant Glioma, Refractory WHO Grade II Glioma, Refractory WHO Grade III Glioma
Interventions: Arm 1: IL13Ra2-specific CAR Tcm cells, Arm 2: IL13Ra2-specific CAR Tcm cells, Arm 3: IL13Ra2-specific CAR Tcm cells, Arm 4: IL13Ra2-specific CAR Tcm cells, Arm 5: IL13Ra2-specific CAR Tn/mem cells, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopic Imaging, Quality-of-Life Assessment; Biological · Other · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 12 Years to 75 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Congenital Heart Disease
Interventions: Pulmonary Valve Replacement Surgery; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: 18 Months to 16 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2036
U.S. locations: 12
States / cities: Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 9 more

Conditions: Vaginismus, Dyspareunia
Interventions: Milli Vaginal Dilator; Device
Lead sponsor: Materna Medical; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Mountain View, California

Conditions: Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
Interventions: RMC-6291; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 15
States / cities: Springdale, Arkansas • Orange, California • Sacramento, California + 10 more

Conditions: Lower-Limb Amputation
Interventions: Exercise self-management, Attention control; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years to 89 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Gastrointestinal Cancer, Gastrointestinal Disease, Nurse's Role
Interventions: Partnership, Assessment, Care and Transition training intervention; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Alcohol Drinking, Alcohol Use Disorder, Alcohol Intoxication, Alcohol; Harmful Use, Alcoholism, Binge Drinking
Interventions: Alcohol, Placebo; Drug · Other
Lead sponsor: Carnegie Mellon University; Other
Eligibility: 21 Years to 29 Years
Enrollment: 782 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hair Reduction, Tattoo Removal, Wrinkle, Acne, Scars, Benign Cutaneous Vascular Lesions, Skin Conditions
Interventions: Nordlys, Gentle, Picoway, Vbeam, Profound, Profound Matrix, eTwo, Exceed, CO2RE; Device
Lead sponsor: Candela Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2029
U.S. locations: 2
States / cities: Jacksonville, Florida • Marlborough, Massachusetts

Search by objective public record fields.

Glutamatergic Mechanisms of Psychosis and Target Engagement (SA1)

A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study

Treating Patients With Melanoma and ALK Alterations With Ensartinib

Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Patient-Centered Decision Support for Eosinophilic Esophagitis

Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function

Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer

Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors

Open Pilot Trial of BHV-4157

A Prospective, Clinical Investigation of the Vanguard 360 Revision Knee

A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function

A Prospective Natural History Study in Uveal Melanoma

Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma

Autus Valve Pivotal Study

Prospective on Market Patient-reported Outcomes for Milli

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Walking Exercise Sustainability Through Telehealth for Veterans With Lower-limb Amputation

Advancing Nursing Practices in Hospital Oncology Care

Behavioral Alcohol Responses (BAR) Study

Clinical Study to Evaluate the Safety and Efficacy of Candela Technology